T1	p 149 150	.
T2	p 167 180	postoperative
T3	p 280 281	a
T4	p 924 952	the United States evaluating
T5	p 1105 1211	surgical patients including those undergoing noncardiac thoracic and pelvic operations who were identified
T6	p 1215 1231	moderate to high
T7	p 1257 1267	included .
T8	p 1454 1513	. Eight hundred and eighty eight patients were entered into
T9	p 1552 1555	the
T10	i 547 584	dihydroergotamine ( DHE ) and heparin
T11	i 982 1012	DHE 0.5 mg plus heparin 5000 U
T12	i 1015 1045	DHE 0.5 mg plus heparin 2500 U
T13	i 1048 1062	heparin 5000 U
T14	i 1069 1096	DHE 0.5 mg versus placebo .
T15	i 1431 1437	RFUT )
T16	i 1620 1627	DHE/Hep
T17	i 1645 1652	placebo
T18	i 1696 1702	active
T19	o 126 150	deep venous thrombosis .
T20	o 181 205	deep venous thrombosis (
T21	o 308 326	venous endothelial
T22	o 613 619	stasis
T23	o 970 978	efficacy
T24	o 1241 1247	postop
T25	o 1431 1437	RFUT )